The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro. Read this story
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro. Read this story
More from CNBC | Business Biotechnology Biotech and Pharmaceuticals Pharmaceuticals Health care industry Novo Nordisk A S Eli Lilly and Co Social issues Breaking news business news cnbc Articles US: News Companies Business News Health & Science source:tagname:CNBC US Source